Cytokinetics, Incorporated (CYTK) — Financial statements
Income statement, balance sheet, and cash flow for Cytokinetics, Incorporated — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 88↑376.6% | 18↑145.3% | 8↓92.0% | 95↑34.3% | 70 | |
| Cost of Revenue | 10↓97.0% | 339↑2.8% | 330↑37.1% | 241↑50.6% | 160 | |
| Gross Profit | 78↑124.3% | -321↑0.5% | -323↓120.6% | -146↓63.4% | -90 | |
| Operating Expenses | ||||||
| R&D Expenses | 406↑19.6% | 339↑2.8% | 330↑37.1% | 241↑50.6% | 160 | |
| General & Administrative Expenses | 284↑32.0% | 215↑24.0% | 174↓2.5% | 178↑83.9% | 97 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 284↑32.0% | 215↑24.0% | 174↓2.5% | 178↑83.9% | 97 | |
| Other Expenses | 0.00↑100.0% | -339↓2.8% | -330↓37.1% | -241↓50.6% | -160 | |
| Operating Expenses | 690↑220.5% | 215↑24.0% | 174↓2.5% | 178↑83.9% | 97 | |
| Total Costs & Expenses | 700↑26.2% | 555↑10.1% | 504↑20.3% | 419↑63.1% | 257 | |
| Operating Results | ||||||
| Operating Income | -612↓14.2% | -536↓8.1% | -496↓53.1% | -324↓74.0% | -186 | |
| Depreciation & Amortization | 10↑1.6% | 10↓19.9% | 12↑41.6% | 8↓12.8% | 10 | |
| EBITDA | -775↓57.1% | -493↓8.1% | -457↓38.6% | -329↓86.8% | -176 | |
| EBIT | -785↓56.1% | -503↓7.3% | -469↓38.7% | -338↓81.6% | -186 | |
| Interest & Other Income | ||||||
| Net Interest Income | -55↓58.5% | -35↓16.4% | -30↑24.6% | -40↓37.3% | -29 | |
| Interest Income | 48↓6.0% | 52↑86.5% | 28↑143.6% | 11↑3326.6% | 0.33 | |
| Interest Expense | 104↑20.1% | 87↑50.0% | 58↑12.7% | 51↑74.4% | 29 | |
| Non-Operating Income | 173↑619.6% | -33↓20.3% | -28↓303.2% | 14↑4207.9% | -0.33 | |
| Other Income / Expenses | -173↓224.1% | -53↓77.4% | -30↑53.6% | -65↓123.3% | -29 | |
| Income Before Tax | -785↓33.2% | -590↓12.0% | -526↓35.3% | -389↓80.6% | -215 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -785↓33.2% | -590↓12.0% | -526↓35.3% | -389↓80.6% | -215 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -785↓33.2% | -590↓12.0% | -526↓35.3% | -389↓80.6% | -215 | |
| Bottom-Line Net Income | -785↓33.2% | -590↓12.0% | -526↓35.3% | -389↓80.6% | -215 | |
| EPS (Basic) | -6.54↓24.3% | -5.26↑3.5% | -5.45↓25.9% | -4.33↓54.6% | -2.80 | |
| EPS (Diluted) | -6.54↓24.3% | -5.26↑3.5% | -5.45↓25.9% | -4.33↓54.6% | -2.80 | |
| Weighted Average Shares | 120↑7.2% | 112↑16.0% | 97↑7.5% | 90↑16.8% | 77 | |
| Weighted Average Diluted Shares | 120↑7.3% | 112↑16.0% | 97↑7.5% | 90↑16.8% | 77 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.